Critical Appraisal Kel B

Download as pptx, pdf, or txt
Download as pptx, pdf, or txt
You are on page 1of 9

CRITICAL APPRAISAL

OF THE TOPIC

dr. Siti Aisyah 131921200001 dr. Alhan Rao 131921200005


dr. Muhammad Hilmy Ayundra 130221200002 dr. Aji Prasetyo Utomo 132321200001
dr. Ambara Rakhmadi Shabana 130321200002 dr. Erick Maulana Yusup 131421200003
ARTICLE INFORMATION
• Received fot published : 09 August 2018
• Published in a manner online : 05 February 2019
• DOI: doi.org/10.1038/s41698-018-0076-8
• Cost/Support : Not there
FILTERING FOR VALIDITY EARLY AND RELEVANCE

1. Is the article a peer-reviewed journal ? Yes


2. Is this research location , if valid, will be used for the
benefit of my practice ? Yes.
3. Whether this research is sponsored by an organization
that may be involved in the design of the research data ?
No.
FILTERING FOR VALIDITY EARLY AND RELEVANCE

4. Would this information, if true, have a direct impact on the


health of my patients and will it be meaningful to them ?
Yes.
5. Whether this problem is something that is frequently
encountered in my place of practice, and whether the
intervention or test can be used and is available for me to
use ? No.
6. Would this information, if correct, lead me to change my
current practice ? Yes.
LEVEL 1 OF EVIDENCE
Therapy / Prevention,
Level Prognosis Diagnosis
Aetiology/ Harm

SR (with homogeneity *) of SR (with homogeneity *) of Level 1


1a SR (with homogeneity *) of RCTs inception cohort studies; CDR † diagnostic studies; CDR † with 1b
validated in different populations studies from different clinical centers

Individual inception cohort study Validating ** cohort study with


Individual RCT (with narrow
1b Confidence Interval ‡)
with > 80% follow-up; CDR † good †††reference standards; orCDR †
validated in a single population tested within one clinical center

1c All or none All or none case-series Absolute SpPins and SnNouts††


LEVEL 2 OF EVIDENCE
Therapy / Prevention,
Level Prognosis Diagnosis
Aetiology/ Harm

SR (with homogeneity *) of
SR (with homogeneity * ) of cohort either retrospective cohort SR (with homogeneity *) of Level> 2
2a studies studies or untreated control diagnostic studies
groups in RCTs

Retrospective cohort study or Exploratory ** cohort study with


Individual cohort study (including follow-up of untreated control good †††reference standards; CDR †
2b low quality RCT; eg, <80% follow-up) patients in an RCT; Derivation of after derivation, or validated only on
CDR † or validated on split- split-sample or databases
sample only

"Outcomes" Research; Ecological


2c studies "Outcomes" Research
LEVEL 3,4,5 OF EVIDENCE
Therapy / Prevention,
Level Prognosis Diagnosis
Aetiology/ Harm
SR (with homogeneity *) of case- SR (with homogeneity *) of 3b and
3a control studies better studies

Non-consecutive study; or without


3b Individual Case-Control Study consistently applied reference
standards

Case-series (and Case-series (and


Case-control study, poor or non-
4 poor quality cohort and case-control poor quality prognostic cohort st
independent reference standard
studies§§ udies ***
) )

Expert opinion without explicit Expert opinion without explicit Expert opinion without explicit critical
critical appraisal, or based on critical appraisal, or based on
5 physiology, bench research or "first physiology, bench research or
appraisal, or based on physiology,
bench research or "first principles"
principles" "first principles"
GRADE OF RECOMMENDATION
A consistent level 1 studies

B consistent level 2 or 3 studies or extrapolations from


level 1 studies
C level 4 studies or extrapolations from level 2 or 3
studies
D level 5 evidence or troublingly inconsistent or
inconclusive studies of any level
TERIMAKASIH

You might also like